Literature DB >> 11115841

Molecular evolution of multiple recurrent cancers of the bladder.

A A van Tilborg1, A de Vries, M de Bont, L E Groenfeld, T H van der Kwast, E C Zwarthoff.   

Abstract

We describe the reconstruction of bladder tumor development in individual patients spanning periods of up to 17 years. Genomic alterations detected in the tumors were used for hierarchical cluster analysis of tumor subclones. The cluster analysis highlights the clonal relationship between tumors from each patient. Based on the cluster data we were able to reconstruct the evolution of tumors in a genetic tree, where tumors with few aberrations precede those with many genetic insults. The sequential order of the tumors in these pedigrees differs from the chronological order in which the tumors appear. Thus, a tumor with few alterations can be occult for years following removal of a more deranged derivative. Extensive genetic damage is seen to accumulate during the evolution of the tumors. To explain the type and extent of genetic damage in combination with the low stage and grade of these tumors, we hypothesize that in bladder cancer pathogenesis an increased rate of mitotic recombination is acquired early in the tumorigenic process.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11115841     DOI: 10.1093/hmg/9.20.2973

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  22 in total

1.  Preferential allelic deletion of RBSP3, LIMD1 and CDC25A in head and neck squamous cell carcinoma: Implication in cancer screening and early detection.

Authors:  Shreya Sarkar; Chinmay Kumar Panda
Journal:  Cancer Biol Ther       Date:  2018-04-13       Impact factor: 4.742

Review 2.  Toward personalized management in bladder cancer: the promise of novel molecular taxonomy.

Authors:  Marie-Lisa Eich; Lars Dyrskjøt; George J Netto
Journal:  Virchows Arch       Date:  2017-04-21       Impact factor: 4.064

Review 3.  The route to personalized medicine in bladder cancer: where do we stand?

Authors:  Francesco Massari; Chiara Ciccarese; Matteo Santoni; Matteo Brunelli; Alessandro Conti; Alessandra Modena; Rodolfo Montironi; Daniele Santini; Liang Cheng; Guido Martignoni; Stefano Cascinu; Giampaolo Tortora
Journal:  Target Oncol       Date:  2015-01-30       Impact factor: 4.493

Review 4.  Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.

Authors:  Margaret A Knowles; Carolyn D Hurst
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

5.  Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis.

Authors:  Eric Letouzé; Yves Allory; Marc A Bollet; François Radvanyi; Frédéric Guyon
Journal:  Genome Biol       Date:  2010-07-22       Impact factor: 13.583

6.  FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

Authors:  Lucie C Kompier; Irene Lurkin; Madelon N M van der Aa; Bas W G van Rhijn; Theo H van der Kwast; Ellen C Zwarthoff
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

Review 7.  Molecular pathogenesis of bladder cancer.

Authors:  Margaret A Knowles
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

8.  Intestinal adenomas can develop with a stable karyotype and stable microsatellites.

Authors:  Kevin M Haigis; James G Caya; Mark Reichelderfer; William F Dove
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

9.  Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR.

Authors:  L Dyrskjøt; T Reinert; A Novoradovsky; T C M Zuiverloon; W Beukers; E Zwarthoff; N Malats; F X Real; U Segersten; P-U Malmström; M Knowles; C Hurst; J Sorge; M Borre; T F Orntoft
Journal:  Br J Cancer       Date:  2012-09-13       Impact factor: 7.640

10.  Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.

Authors:  Beth Sherrill; James A Kaye; Rickard Sandin; Joseph C Cappelleri; Connie Chen
Journal:  Onco Targets Ther       Date:  2012-10-23       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.